Keros Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
All right. Welcome, everyone, to Day 3 of our healthcare conference. This is Gavin Clark-Gardner with the Evercore ISI biotech research team. And I'm very happy to be here with Keros Therapeutics Inc. CEO, Jasbir Seehra. Jas, thanks for joining us.
Questions & Answers
And we only have 20 minutes for this fireside, so we're actually going to dive right into Q&A. And maybe a good place to start is kind of giving us some brief overview of the history of the company. So when was it founded? What was the initial strategy and focus, and how has that changed or not changed over time?
Gavin, thanks for giving this opportunity first of all. And then with respect to your question, the company was, I believe, registered in December of 2015. We got our Series A in 2016, and my focus always was going to be on the TGF-beta pathway. But as always is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
